Clinical‐Stage Nanatinostat Triggers Productive Epstein‐Barr Virus Lytic Replication
Journal of Medical Virology · 2026-08 · 98 (8)
DOI: 10.1002/jmv.71077 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, online erschienen am 28.07.2026. Verfasst von Ibukun A Akinyemi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Child Health Research Institute, Department of Pediatrics, University of Florida, Gainesville, Florida, USA. Hauptthemen laut MEDLINE: Herpesvirus 4, Human, Virus Replication, Antiviral Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDCR NIH HHS, NCI NIH HHS, Viracta Therapeutics.
Abstract (Originalsprache)
A phase 1b/2 study of the all‐oral “kick‐and‐kill” combo nanatinostat + valganciclovir (nana‐val) showed a ~40% overall response rate in patients with relapsed/refractory Epstein‐Barr virus (EBV)‐associated lymphomas. Despite the promising results in these difficult‐to‐treat cancers, there is little known about the effects of nanatinostat on EBV and cell death. In this work we demonstrate that nanatinostat, an HDAC1/3 inhibitor, robustly induces the full EBV lytic cycle in a panel of EBV‐positive lymphoma and transformed cell lines (Burkitt, DLBCL, lymphoblastoid), spanning viral latency types and EBV genotypes. Nanatinostat drives lytic‐gene transcription across all kinetic classes, viral genome replication, and virion release, and kills cells at nanomolar concentrations. Although valganciclovir does not increase cytotoxicity, its ability to block viral DNA synthesis and virion production justifies its inclusion to prevent viral dissemination. Importantly, the two main metabolites of nanatinostat lack histone‐H3 acetylation activity and neither activate nor inhibit the EBV lytic phase, indicating that they are biologically inert with respect to EBV. These mechanistic insights clarify the clinical efficacy of nana‐val and support further development of kick‐and‐kill strategies for EBV‐driven malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Child Health Research Institute, Department of Pediatrics, University of Florida, Gainesville, Florida, USA.
- Division of Infectious Diseases, Department of Pediatrics, University of Florida, Gainesville, Florida, USA.
- Viracta Therapeutics, Encinitas, California, USA.
- AbVir Therapeutics, California, USA.
- Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, Florida, USA.
Förderung
- NIDCR NIH HHS
- NCI NIH HHS
- Viracta Therapeutics
Zitieren
APA
Akinyemi, I. A., Zeigler, T. M., Willman, G. H., Patel, D., El-Guindy, A., McIntosh, M. T., & Bhaduri-McIntosh, S. (2026). Clinical‐Stage Nanatinostat Triggers Productive Epstein‐Barr Virus Lytic Replication. Journal of Medical Virology, 98(8). https://doi.org/10.1002/jmv.71077
Vancouver
Akinyemi IA, Zeigler TM, Willman GH, Patel D, El-Guindy A, McIntosh MT, et al. Clinical‐Stage Nanatinostat Triggers Productive Epstein‐Barr Virus Lytic Replication. Journal of Medical Virology. 2026;98(8). doi:10.1002/jmv.71077
BibTeX
@article{Akinyemi2026,
author = {Akinyemi, Ibukun A and Zeigler, Travis M and Willman, Griffin H and Patel, Devshree and El-Guindy, Ayman and McIntosh, Michael T and Bhaduri-McIntosh, Sumita},
title = {Clinical‐Stage Nanatinostat Triggers Productive Epstein‐Barr Virus Lytic Replication},
journal = {Journal of Medical Virology},
year = {2026},
volume = {98},
number = {8},
doi = {10.1002/jmv.71077}
}
EUVIMED